The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.

A compound is provided for oral administration of dehydroepiandrosterone (DHEA) derivatives to a human so as to improve at least one of adrenal hormonal balance, improved immune system function, reduction of adipose tissue, skeletal muscle growth, reduction of abdominal bloating, improved recovery from training, increased strength, and increased endurance. The compound includes a first portion comprised of any one of 3a-enanthoxy-5a-androstan-17-one, 3b-undecyloxy-5a-androstan-17-one, and 3b-hydroxy-androstane-3b-ol-one. A second portion of the compound is comprised of 6,7-dihydrogergamottin. A third portion is comprised of piperine, and a fourth portion is comprised of any one or more of rice flour, gelatin, magnesium stearate, and silica. The compound preferably is administered in capsule form one or two times in a 24-hour period.

A compound is provided for oral administration of dehydroepiandrosterone (DHEA) derivatives to a human so as to improve at least one of adrenal hormonal balance, improved immune system function, reduction of adipose tissue, skeletal muscle growth, reduction of abdominal bloating, improved recovery from training, increased strength, and increased endurance. The compound includes a first portion comprised of any one of 3a-enanthoxy-5a-androstan-17-one, 3b-undecyloxy-5a-androstan-17-one, and 3b-hydroxy-androstane-3b-ol-one. A second portion of the compound is comprised of 6,7-dihydrogergamottin. A third portion is comprised of piperine, and a fourth portion is comprised of any one or more of rice flour, gelatin, magnesium stearate, and silica. The compound preferably is administered in capsule form one or two times in a 24-hour period.

This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder. In certain embodiments, the neurokinin 3 receptor antagonist is (R)—N-{{3-[1-Benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1-yl}-4-phenylpiperidin-4-yl}-N-methylacetamine or salts thereof.